EVENITY
EVENITY is a fast-acting, high-efficacy treatment for severe osteoporosis in postmenopausal women. With measurable fracture risk reduction and BMD improvements in just 12 months, it’s an effective frontline or rescue therapy when other agents fail. For practices focused on outcomes, EVENITY offers both speed and durability—with results that continue after transition to standard antiresorptives.
Contact Doctor Medica’s customer service representatives for guidance on how to order Evenity online.
We Bring the Best Solutions to You. Register Now
Join us in discovering the perfect medical and aesthetic solutions for your clinic. By registering, you'll receive personalized consultations that connect you with an extensive selection of products– tailored to your clinic's distinctive needs and aspirations.
EVENITY at a Glance
EVENITY® is a once-monthly injectable treatment for postmenopausal osteoporosis at high fracture risk. It works by inhibiting sclerostin, increasing bone formation and reducing resorption.- Dose: 210 mg SC, given as two 105 mg injections once monthly
- Use limit: 12 doses (1 year max)
- Mechanism: Dual-action—bone formation + anti-resorption
Performance Benefits for Clinical Use
EVENITY delivers rapid BMD increases and reduces fracture risk across high-risk patient populations.- 73% relative reduction in new vertebral fractures at 12 months
- 75% reduction in vertebral fractures at 24 months with follow-up antiresorptive use
- 13% increase in lumbar spine BMD at 12 months
- 8.1% lumbar spine BMD gain sustained at 24 months with sequential alendronate
- Outperforms alendronate in BMD gains and fracture prevention
Ideal EVENITY Use Cases and Patient Profiles
Indicated for postmenopausal women with osteoporosis at high risk for fracture—especially those who:- Have a prior osteoporotic fracture
- Have multiple fracture risk factors
- Are intolerant or unresponsive to other osteoporosis treatments
EVENITY Core Ingredients and Their Roles
Each prefilled syringe contains romosozumab-aqqg, a humanized monoclonal antibody.- Active: Romosozumab-aqqg 105 mg/1.17 mL
- Excipients: Sucrose, calcium, acetate, polysorbate 20, sodium hydroxide, water for injection
- pH adjusted to 5.2
EVENITY Injection Techniques and Application Guide
EVENITY must be administered by a healthcare professional. Each monthly dose requires two injections.- Dose: 210 mg SC monthly, via two 105 mg prefilled syringes
- Sites: Abdomen, thigh, or upper arm
- Rotate injection sites; avoid irritated or scarred skin
- Missed dose: Reschedule promptly; resume monthly from new date
- Supplement with calcium and vitamin D throughout treatment
EVENITY Storage, Shelf Life, and Handling
Proper storage is critical for drug stability and efficacy.- Refrigerate at 2–8°C (36–46°F) in original carton
- Do not freeze or shake
- At room temp (max 25°C/77°F): stable for up to 30 days
- Inspect prior to use: solution should be clear to light yellow, free of particles
EVENITY Side Effects: What to Monitor
Monitor patients for both common and serious events. Common (≥5%):- Arthralgia
- Headache
- Cardiovascular: MI, stroke, cardiovascular death—hazard ratio 1.87 vs alendronate
- Hypocalcemia: Especially in renal impairment; correct before starting
- ONJ and atypical femoral fractures: Evaluate dental health and thigh/groin pain
- Hypersensitivity: Angioedema, rash, urticaria—discontinue if reaction occurs
Key Practitioner Questions About EVENITY Answered
How long can EVENITY be used?- 12 months max. Afterward, transition to an antiresorptive agent.
- Yes, but follow-up with denosumab or alendronate sustains BMD gains.
- No. Must be administered by a licensed provider.
- No dose adjustment needed, but monitor calcium in severe impairment or dialysis.
- Without follow-up treatment, BMD returns to baseline within 12 months
